

CNS remyelination and the innate immune system

Christopher E. McMurran¹, Clare A. Jones², Denise C. Fitzgerald³, Robin J. Franklin^{1*}

¹Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, United Kingdom, ²MedImmune, United Kingdom, ³School of Medicine, Dentistry and Biomedical Science, Centre for Infection and Immunity, United Kingdom

Submitted to Journal:
Frontiers in Cell and Developmental Biology

Specialty Section:
Molecular Medicine

ISSN:
2296-634X

Article type:
Review Article

Received on:
01 Mar 2016

Accepted on:
18 Apr 2016

Provisional PDF published on:
18 Apr 2016

Frontiers website link:
www.frontiersin.org

Citation:
McMurran CE, Jones CA, Fitzgerald DC and Franklin RJ (2016) CNS remyelination and the innate immune system. *Front. Cell Dev. Biol.* 4:38. doi:10.3389/fcell.2016.00038

Copyright statement:
© 2016 McMurran, Jones, Fitzgerald and Franklin. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](http://creativecommons.org/licenses/by/4.0/). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

CNS remyelination and the innate immune system

Christopher E McMurran¹, Clare A Jones², Denise C Fitzgerald³, Robin JM Franklin¹

¹Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Clifford Allbutt Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AH, UK

²MedImmune, Granta Park, Great Abington, CB21 6GH, UK

³Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Science, Queens University Belfast, Northern Ireland, UK

* Correspondence:

Prof Robin Franklin, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Clifford Allbutt Building, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AH, UK

rjf1000@cam.ac.uk

Keywords: remyelination, inflammation, innate immune system, microglia, macrophage

Abstract

A misguided inflammatory response is frequently implicated in myelin damage. Particularly prominent among myelin diseases, multiple sclerosis (MS) is an autoimmune condition, with immune-mediated damage central to its aetiology. Nevertheless, a robust inflammatory response is also essential for the efficient regeneration of myelin sheaths after such injury. Here, we discuss the functions of inflammation that promote remyelination, and how these have been experimentally disentangled from the pathological facets of the immune response. We focus on the contributions that resident microglia and monocyte-derived macrophages make to remyelination and compare the roles of these two populations of innate immune cells. Finally, the current literature is framed in the context of developing therapies that manipulate the innate immune response to promote remyelination in clinical myelin disease.

1 Remyelination: regeneration in the CNS

The mammalian central nervous system (CNS) is often considered an archetypal example of a tissue with poor regenerative potential. This is exemplified by clinical conditions such as spinal cord injury, stroke and Alzheimer's disease, where prognosis is poor due to limited regeneration of neurons and axons (1). Myelin sheaths, however, are an important exception to this dogma, being a component of the CNS that *can* regenerate robustly with good functional outcome; a process termed remyelination (2).

Myelin sheaths are made up of layers of lipid-rich dielectric membrane wrapped around axons to which they provide electrical insulation and trophic support (3). This membrane is produced by specialised glial cells: oligodendrocytes in the CNS, or Schwann cells in the peripheral nervous

system (PNS). The loss of myelin sheaths with preservation of the underlying axon is known as demyelination. This is sometimes referred to as primary demyelination to distinguish it from secondary demyelination, where myelin loss occurs as a consequence of axonal loss. This latter process is more accurately referred to as Wallerian degeneration, and we regard the use of the term demyelination in this situation as confusing and misleading.

Remyelination involves the reinvestment of new myelin sheaths around intact axons from which they have been lost (i.e. demyelination) (2). This process is performed by newly generated oligodendrocytes that derive from a pool of oligodendrocyte progenitor cells (OPCs) following a demyelinating insult. OPCs are present throughout both grey and white matter in the CNS, and have “stem cell-like” properties such as multipotency and self-renewal (4). In response to demyelination, OPCs proliferate and migrate to the lesion site (5,6) where they differentiate to mature oligodendrocytes or Schwann cells, extending processes to remyelinate denuded axons (7). Consequently, saltatory conduction is restored (8) and axons are generally protected from further degeneration (9). In some paradigms, whilst axons are not fully protected, their degeneration is substantially delayed with motor deficits not re-appearing until much later timepoints (10).

Whilst originally characterised in animal models (11), remyelination is also seen in human patients with MS (12). Amongst MS lesions there is an association between remyelination and preservation of axons (13), although it is in practice difficult to assess whether remyelination occurs because axons have survived, or the axons have survived because they are remyelinated. Whilst extensive in some cases, remyelination efficiency falls as the disease progresses, so it is usually insufficient to prevent a patient’s neurological decline as damage gradually accumulates (14,15).

Crucially, regenerative processes become less efficient with increasing age, and remyelination is no exception (16). This tenet of regenerative medicine is particularly relevant in a chronic disease such as MS, which spans several decades (17). Ageing brings about intrinsic changes in OPCs (18) and their environmental signals (19), both of which negatively impact remyelination. Because of this age-related decline, many key findings have come from comparing remyelination or clinical outcome in young and old animals (18,19,20) or human cases (21). More interventional approaches have manipulated these systems to identify pathways crucial for efficient remyelination in young animals (22,23,24) or that can rejuvenate remyelination in older animals (25, 26).

When remyelination fails, the limiting step is most commonly OPC differentiation, a term encompassing the establishment of axonal contact, activation of myelin synthesis pathways and the wrapping and compaction of the newly generated sheath (4). In humans, this is evidenced by an abundance of undifferentiated oligodendrocyte lineage cells in many chronic MS lesions, which fail to remyelinate (27,28). Thus, there is much clinical need for therapies to enhance OPC differentiation and endogenous remyelination. One avenue for this is to target the innate immune system.

2 Innate immune cells of the CNS

The immune system is the network of cellular and molecular elements that protect an organism from disease. In vertebrates, it can broadly be divided into the innate and the adaptive immune systems, though these two branches communicate extensively and various components, such as innate lymphoid cells, share features of both. In general, the innate immune system responds rapidly and relatively non-specifically to infection or damage, whilst the adaptive immune system mounts a slower, long-lasting response to specific targets. Inflammation describes an immune-mediated response to stimuli that are perceived as harmful, such as invading pathogens or tissue damage.

Like other tissues, the CNS has its own battalion of resident tissue macrophages, called microglia. These are innate immune cells that, in the healthy brain, serve physiological functions in synaptic plasticity (29) and clearance of debris (30). Meanwhile, microglia continuously survey their microenvironment for stimuli that might indicate injury or infection, and are ready to respond to this by entering an activated state characterised by cytokine secretion, phagocytosis and, on occasions, direct cytotoxicity (31).

After such a stimulus, microglia may be supplemented by a second population of macrophages from the periphery. These differentiate from blood monocytes that have infiltrated the CNS in response to tissue damage, and thus originate in the bone marrow. Key differences exist between resident microglia and these monocyte-derived macrophages, including their disparate developmental origins (32), their transcriptomic signatures (33) and capacity for local self-renewal and expansion (34). However, in a demyelinated lesion, both cell types show high levels of activation and only recently have successful attempts been made to phenotypically and functionally distinguish between them, as will be discussed.

Besides microglia and monocyte-derived macrophages, an array of other innate immune cells can be found in a demyelinating lesion. Whilst neutrophils (35), mast cells (36) and dendritic cells (37) can contribute to demyelination, with a disputed role of natural killer cells in promoting/limiting damage (38), little evidence exists to support a substantial contribution of these cell types to remyelination (39). Thus, in our discussion of CNS remyelination and the innate immune system, our focus is primarily on microglia and infiltrating macrophages.

3 Innate immune cells and myelin disease

In MS, aberrant activity of the innate immune system can contribute to myelin damage. The driver of this is a defective adaptive immune response involving autoreactive T cells, but through innate-adaptive cross talk, microglia and monocyte-derived macrophages can be recruited and mediate a substantial part of the damage (40). Based on this aetiology, clinical therapies for MS tend to focus on inhibiting the adaptive immune system. Examples include the monoclonal antibodies natalizumab, which impairs T cell trafficking into the CNS (41), and rituximab, which targets CD20 to deplete autoantibody-producing B cells (42).

A commonly used range of models for MS is experimental autoimmune encephalomyelitis (EAE), in which an inoculated animal develops autoreactive T-cells targeting myelin. This is a useful paradigm for modelling many of the immunogenic features of MS (43). However, the complex inflammatory pathogenesis of these models can mask beneficial regenerative effects of the innate immune system that may occur concurrently with negative, disease-contributing innate cell functions. As such, delineating specific regenerative functions of innate cells and signals in EAE is challenging. In contrast, toxin-induced models of demyelination, such as focal lysolecithin injection, have more discrete phases of demyelination and remyelination. As the myelin damage is initiated directly by the toxin, we can generally assume that immune cell activity during the remyelination phase is a *response* to myelin damage, rather than an on-going cause. We will see how such a response can indeed contribute to the process of remyelination.

4 The critical role of the innate immune system

Making use of these toxin-induced demyelination models, a beneficial role of the innate immune system in remyelination was demonstrated in rats depleted of circulating monocytes (22). This was achieved by systemic treatment with clodronate liposomes, which are toxic to cells that phagocytose them. Treated animals had fewer inflammatory cells in the lesion suggesting a muted innate immune response to tissue damage and, interestingly, a lower proportion of their axons were remyelinated post-lesion.

Conversely, by promoting inflammation it is possible to increase the efficiency of myelin formation. This was shown by using transplanted OPCs to myelinate retinal ganglion cell axons, which are normally unmyelinated prior to where they form the optic nerve (44). Administration of the Toll-Like Receptor 2 agonist zymosan greatly increased the number of activated macrophages and the degree of myelination by the transplanted OPCs. Thus the link between an inflammatory response and remyelination has been shown in both “loss-of-function” and “gain of function” experiments.

A beneficial role of the innate immune system in remyelination is less clear-cut in models where inflammation also contributes to the damage. In EAE, similar to MS, both microglia and infiltrating monocytes are implicated in demyelination (45,46,47). However, evidence also suggests that subsets of these cells can play beneficial roles in limiting damage and promoting remyelination. Macrophages can modulate their phenotypes in response to extracellular cues (48), often termed “M1” (pro-inflammatory) or “M2” (anti-inflammatory) polarisation for convenience, though in reality representing a spectrum with a broad degree of plasticity (49). A shift towards the anti-inflammatory M2 phenotype is associated with a milder clinical picture in EAE (50), and administration of M2-polarised monocytes to EAE animals can enhance differentiation of oligodendrocytes and improve symptoms (51). This is consistent with a crucial shift from pro- to anti-inflammatory phenotypes in remyelination of toxin-induced lesions (25). Myeloid-derived suppressor cells are a subpopulation of innate immune cells that typically express M2 markers and limit damage in EAE at peaks of disability, in part by promoting apoptosis of T lymphocytes (52).

Thus, even on a backdrop of inflammatory damage, cells of the innate immune system can play beneficial roles in outcome and may contribute to remyelination. This is important for the application of findings from toxin-induced models to the immune-mediated pathology of MS. Indeed, post-mortem data from MS patients, shows a correlation between the density of macrophages and the density of OPCs within a lesion (53). MS lesions can be classified by their histopathology: active plaques, which have on-going inflammation, show the highest levels of OPC recruitment and remyelination, whilst chronic active and chronic inactive plaques show little inflammation and remyelination is rare (54). Lesions that remyelinate successfully become shadow plaques, in which axons are relatively preserved. Reactivation of inflammation in chronic plaques may be a strategy to overcome their remyelination failure (2).

The decline of remyelination efficiency with age also occurs in part at the level of the innate immune system. This was demonstrated using a heterochronic parabiosis system, in which mice of different ages are connected via their circulatory systems (26). Remyelination of a toxin-induced lesion is rejuvenated in old mice that are exposed to the systemic environment of a younger mouse. The effect was abrogated in mice that lacked CCR2, a receptor necessary for monocyte entry into the CNS, suggesting that young macrophages are able to stimulate old OPCs to differentiate more efficiently. A timely shift from pro- to anti-inflammatory innate immune cell phenotypes is important for efficient remyelination (25), a phenomenon also seen in regeneration of other tissues, including skin (55). This shift is diminished with ageing, but rejuvenated by heterochronic parabiosis (25), and appears to be instrumental in the rejuvenation of remyelination.

The positive relationship between remyelination and inflammation is strikingly similar to results seen across a broad range of regeneration paradigms. Healing of other murine tissues such as skin (56) is impaired when macrophages are subject to selective genetic ablation. The famously extensive regrowth of salamander limbs after amputation is also diminished when macrophages are depleted by a toxic liposome treatment (57). Even in the planarian flatworm, a remarkable organism capable of regenerating any of its tissues after transection, primitive macrophage-like cells are abundant at the site of injury (58). The conservation of this phenomenon across the animal kingdom gives further weight to the idea that remyelination requires a robust inflammatory response.

5 How do innate immune cells contribute to remyelination?

The most important functions of innate immune cells in remyelination appear to be 1) phagocytosis of debris and 2) secretion of growth signals, cytokines and other factors. Through a combination of these mechanisms, microglia and monocyte-derived macrophages can fashion a pro-regenerative environment that maximises the potential of OPCs to differentiate and replace the myelin on denuded axons (Fig. 1).

Macrophages are well known for their phagocytosis of invading pathogens, cellular debris and apoptotic host cells. In a lesion where myelin sheaths are destroyed, much of this phagocytic response is directed towards fragments of myelin, which can linger in the environment. CNS myelin inhibits OPC differentiation *in vitro* (59) and *in vivo* it was shown that remyelination is impaired if a lesion is supplemented with additional myelin debris (60). This would suggest that clearance of myelin debris by phagocytosis is necessary for OPCs to produce new oligodendrocytes. More direct evidence for this comes from recent studies showing reduced remyelination when phagocytosis is specifically impaired in microglia (CX3CR1 knockout, (23)) or in infiltrating macrophages (LysM-specific RXR α knockout, (24)).

Inflammation can also contribute to remyelination through phagocytosis-independent mechanisms. This is apparent during the enhanced myelination of retinal ganglion cells by transplanted OPCs when inflammation is stimulated (44). These axons are not myelinated under normal conditions, so there is accordingly no myelin debris for innate immune cells to clear. Innate immune cells can secrete a wide array of factors that contribute to the lesion environment, and these are disturbed in older animals, which have a lower capacity for remyelination (19,20). The ability of microglia-conditioned media to modulate OPC behaviour *in vitro* is further evidence of secreted factors promoting remyelination. Media conditioned by pro-inflammatory M1 microglia, which appear soon after a lesion, promote OPC proliferation, whilst media conditioned by M2 anti-inflammatory microglia, which peak later, prevent apoptosis and encourage differentiation to oligodendrocytes (25).

Several specific factors are known to be produced during inflammation and promote remyelination. Insulin-like growth factor (IGF-1) and transforming growth factor- β (TGF- β) have long been known to promote OPC differentiation *in vivo* (61,62) and their expression is delayed in the slow remyelination of old rats (20). More recently, endothelin 2 was identified by transcriptional profiling of the OPC retinal transplant model (63) and activin-A was found to be essential for the microglia-conditioned media effects on OPC differentiation (25). The msh-like homeobox-3 gene (*Msx3*) appears to be an important positive regulator for the M2 phenotype and for expression of activin-A and IGF-1. Overexpression of *Msx3* in transplanted microglia enhances remyelination in both EAE and lysolecithin models (64).

6 Divergent roles for macrophages and microglia

The two key functions of phagocytosis and mediator secretion can be carried out by both resident microglia and infiltrating macrophages, which are often discussed as a single functional population. However, as our models of remyelination and the tools to probe them become more sophisticated, more differences between these two pools of innate immune cells are emerging.

A comparison of the transcriptomes of microglia and peripherally-derived macrophages revealed several hundred genes that could distinguish between the two populations, largely related to sensing endogenous ligands and microbes (33). This may become less pronounced when microglia become activated in a lesion environment, as inflammatory stimuli can substantially alter the microglial transcriptome (65). Nevertheless, it is possible to determine the origin of innate immune cells in EAE lesions based on maintained molecular signatures: notably, the microglial-specific surface markers P2ry12, FCRL5 (66) and Tmem119 (67) are maintained during inflammation, and are not upregulated in monocyte-derived macrophages. Prior to these recent advances, the use of blood-brain barrier impermeable toxins have been used to specifically ablate peripherally-derived macrophages, whilst fluorescent bone-marrow chimeras have allowed peripheral cells to be tracked upon entry to the CNS.

These techniques have demonstrated how microglia and infiltrating macrophages have a high degree of overlap in their function. Microglia appear to undergo a compensatory proliferation in lesions lacking monocyte-derived macrophages due to peripheral ablation (68). Using a green fluorescent protein-positive (GFP⁺) bone marrow chimera, it was shown that the transition from M1 to M2 phenotypes occurs similarly in both microglia and infiltrating macrophages after a lysolecithin-induced lesion (25). The infiltration of young monocytes into an old lesion in the heterochronic parabiosis model accelerates the shift from M1 dominance to M2 dominance within the lesion and likely contributes to the enhanced remyelination. Relatively few cells in the lesion were derived from a GFP⁺ young partner, suggesting that these infiltrating cells were influencing endogenous innate immune cells to create a pro-regenerative environment.

Other experiments have elucidated divergent functions of microglia and monocyte-derived macrophages in remyelination. When demyelination was induced by dietary cuprizone, blocking peripheral monocyte infiltration by CCR2 deficiency was inconsequential to the regenerative process (23), in contrast to the importance of this process for efficient remyelinating of a stereotactic lysolecithin lesion (26). Endogenous microglia, on the other hand, were shown to be vital as remyelination was impaired in a CX3CR1 microglial receptor knockout mouse model. In the dietary cuprizone model, demyelination occurs without the blood-brain barrier damage of stereotactic injection (69), which may account for the reduced role of monocyte-derived macrophages, though these cells were still able to infiltrate the lesioned CNS (23). Additionally this study did not look at ageing, which may be a context in which CCR2-dependent monocyte recruitment becomes more critical. Divergent roles for endogenous and infiltrating components were also observed when EAE was induced in transgenic mice with green CX3CR2⁺ microglia and red CCR2⁺ macrophages (70). In this case, highly activated monocyte-derived macrophages appear to initiate demyelination, whilst microglia had more beneficial roles in clearing debris.

This rapidly expanding body of evidence is leading us away from a model of a single macrophage/microglia compartment in a demyelinated lesion. Significant transcriptional differences in sensory genes (33) suggest that the two populations can respond differently to the same environmental stimuli. The manifestation of these differences seems to depend strongly on the

experimental model, perhaps implying that differences in age or blood-brain barrier function are important (23,26). In EAE, where the pathology is immune-mediated, infiltrating macrophages and resident microglia may even have opposing roles, promoting de- and re-myelination respectively (70). However, this result contrasts with a beneficial effect of specifically blocking resident microglial activation, even in EAE with the same immunogen (46). In any case, the high variability between experimental setups suggests that the relative contributions of these two innate immune cell populations will likely differ between individual clinical myelin disorders, their stages and lesion types.

7 Inflammatory therapies for regeneration in myelin disease?

A range of clinical diseases involve primary demyelination, the causes of which can be intrinsic or extrinsic to the oligodendrocyte lineage. Intrinsic causes account for the leukodystrophies, in which genetic mutations affect production of myelin proteins and other oligodendrocyte functions. Alternatively, the pathology can originate from the oligodendrocytes' environment, for example inflammation in MS, or toxicity as in many model systems. Whilst cell therapy is a promising avenue for leukodystrophies, diseases that originate externally will most likely benefit from interventions that lessen the demyelinating insult and promote endogenous remyelination (2).

Currently, most disease-modifying drugs used to treat MS focus on modulating the adaptive immune response using small molecules or monoclonal antibodies. These can be effective in reducing the length and frequency of relapses and provide symptomatic relief, though there is limited impact on the progressive phase of the disease and no curative agents are currently in clinical use (71). Modulating the innate immune response to promote endogenous remyelination is a potential means to salvage denuded axons and prevent progression of the disease.

Microglia and infiltrating macrophages promote remyelination through important roles in debris clearance and secretion of factors into their local environment. These two functions become gradually less efficient as an animal ages (26,24,20), though aspects of the decline appear to be reversible by altering the tissue environment (72). Compelling evidence from parabiosis shows that remyelination by previously inefficient OPCs in an old animal can indeed be rejuvenated by manipulating components of the innate immune system (26). Systemic pharmacological activation of the innate immune system has also been shown to promote remyelination (73). Additionally, as we learn more about the differences between microglia and monocyte-derived macrophages, divergent roles may be specifically targeted to enhance the production of a pro-regenerative environment.

However, the immune system is a complex network with much cross-talk between its adaptive and innate branches. Translational challenges will come in being able to stimulate the beneficial functions of innate immune cells without simultaneously fuelling further autoimmune destruction of myelin sheaths. Additionally, many of the symptoms of MS result from the death of axons that have already been too long without the trophic support and protection of myelin (74). Endogenous remyelination could not reverse the symptoms associated with previous axonal death, though it could salvage vulnerable axons at the point between demyelination and death. As such, remyelinating therapies would address an important unmet need in the treatment of demyelinating disease. Such regenerative therapies will likely be additive and complementary to the current disease-modifying treatments that can reduce the occurrence of demyelination with variable risks of adverse effects.

Despite foreseeable challenges, harnessing the pro-regenerative properties of inflammation has shown extensive benefit in animal models of remyelination. This approach has the potential to partially reverse the course of MS when it begins to makes the transition from bench to bedside.

8 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

9 Author Contributions

All four authors contributed to the writing of this article.

10 Funding

The authors would particularly like to acknowledge the support of the UK MS Society, The Jean Shanks Foundation and MedImmune.

11 Acknowledgments

The authors would like to acknowledge the contributions of many members of their respective laboratories who have contributed to much of the work described.

12 References

1. Tanaka EM, Ferretti P. Considering the evolution of regeneration in the central nervous system. *Nat Rev Neurosci.* (2009) **10**:713-23. doi: 10.1038/nrn2707.
2. Franklin RJM, Goldman SA. Glia Disease and Repair - Remyelination. *Cold Spring Harb Perspect Biol.* (2015) **7**:a020594. doi: 10.1101/cshperspect.a020594.
3. Nave K-A, Trapp BD. Axon-glia signaling and the glial support of axon function. *Annu Rev Neurosci.* (2008) **31**:535-61. doi: 10.1146/annurev.neuro.30.051606.094309.
4. Franklin RJM, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. *Nat Rev Neurosci.* (2008) **9**:839-55. doi: 10.1038/nrn2480.
5. Di Bello IC, Dawson MR, Levine JM, Reynolds R. Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. *J Neurocytol.* (1999) **28**:365-81.
6. Crawford AH, Stockley JH, Tripathi RB, Richardson WD, Franklin RJM. Oligodendrocyte progenitors: Adult stem cells of the central nervous system? *Exp Neurol.* (2014) **260**:50-5. doi: 10.1016/j.expneurol.2014.04.027.
7. Zawadzka M, Rivers LE, Fancy SP, Zhao C, Tripathi R, Jamen F et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. *Cell Stem Cell.* (2010) **6**:578-90. doi: 10.1016/j.stem.2010.04.002.
8. Smith KJ, Blakemore WF, McDonald WI. Central remyelination restores secure conduction. *Nature.* (1979). **280**:395-6. doi:10.1038/280395a0.
9. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. *Brain.* (2008) **131**:1464-77. doi: 10.1093/brain/awn080.
10. Manrique-Hoyos N, Jürgens T, Grønborg M, Kreutzfeldt M, Schedensack M, Kuhlmann T et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. *Ann Neurol.* (2012) **71**:227-44. doi: 10.1002/ana.22681.
11. Bunge MB, Bunge RP, Ris H. Ultrastructural study of remyelination in an experimental lesion

- in adult cat spinal cord. *J Biophys Biochem Cytol.* (1961) **10**:67-94.
12. Prineas JW, Connell F. Remyelination in multiple sclerosis. *Ann Neurol.* (1979) **5**:22–31. doi: 10.1002/ana.410050105.
 13. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. *Am J Pathol.* (2000) **157**:267–76. doi: 10.1016/S0002-9440(10)64537-3.
 14. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. *Neurology.* (2009) **72**:1914–21. doi: 10.1212/WNL.0b013e3181a8260a.
 15. Franklin RJM, French-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. *Nat Rev Neurol.* (2012) **8**:624–34. doi: 10.1038/nrneurol.2012.200.
 16. Shields SA, Gilson JM, Blakemore WF, Franklin RJM. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. *Glia.* (1999) **28**:77–83. doi: 10.1002/(SICI)1098-1136(199910)28:1<77::AID-GLIA9>3.0.CO;2-F.
 17. Franklin RJM. Why does remyelination fail in multiple sclerosis? *Nat Rev Neurosci.* (2002) **3**:705–14. doi: 10.1038/nrn917.
 18. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJM, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. *Nat Neurosci.* (2008) **11**:1024–34. doi: 10.1038/nn.2172.
 19. Zhao C, Li WW, Franklin RJM. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. *Neurobiol Aging.* (2006) **27**:1298–307.
 20. Hinks GL, Franklin RJM. Delayed changes in growth factor gene expression during slow remyelination in the CNS of aged rats. *Mol Cell Neurosci.* (2000) **16**:542–56. doi: DOI: 10.1006/mcne.2000.0897.
 21. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. *Brain.* (2006) **129**:595-605. doi: 10.1093/brain/awh714. doi: 10.1093/brain/awh714.
 22. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJM. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. *Glia.* (2001) **35**:204–12. doi: 10.1002/glia.1085.
 23. Lampron A, Larochelle A, Laflamme N, Préfontaine P, Plante MM, Sánchez MG, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. *J Exp Med.* (2015) **212**:481–95. doi: 10.1084/jem.20141656.
 24. Natrajan MS, De La Fuente AG, Crawford AH, Linehan E, Nuñez V, Johnson KR, et al. Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. *Brain.* (2015) **138**:3581–97. doi: 10.1093/brain/awv289.
 25. Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat Neurosci.* (2013) **16**:1211–8. doi: 10.1038/nn.3469.
 26. Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, Wagers AJ, et al. Rejuvenation of regeneration in the aging central nervous system. *Cell Stem Cell.* (2012) **10**:96–103. doi: 10.1016/j.stem.2011.11.019.
 27. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. *J Neurosci.* (1998) **18**:601–9.
 28. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. *Brain.* (2008) **131**:1749–58. doi: 10.1093/brain/awn096

29. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P et al. Synaptic pruning by microglia is necessary for normal brain development. *Science*. (2011) **333**:1456–8. doi: 10.1126/science.1202529.
30. Ferrer I, Bernet E, Soriano E, Del Rio T, Fonseca M. Naturally occurring cell death in the cerebral cortex of the rat and removal of dead cells by transitory phagocytes. *Neuroscience*. (1990) **39**:451–8. doi: 10.1016/0306-4522(90)90281-8.
31. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in vivo. *Science*. (2005) **308**:1314–9. doi: 10.1126/science.1110647.
32. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science*. (2010) **330**:841–5. doi: 10.1126/science.1194637. doi: 10.1126/science.1194637.
33. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. *Nat Neurosci*. (2013) **16**:1896–905. doi: 10.1038/nn.3554.
34. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM V. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat Neurosci*. (2007) **10**:1538–43. doi: 10.1038/nn2014.
35. Liu L, Belkadi A, Darnall L, Hu T, Drescher C, Cotleur AC, et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. *Nat Neurosci*. (2010) **13**:319–26. doi: 10.1038/nn.2491.
36. Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC. Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. *J Neuroimmunol*. (2003) **145**:18–26. doi: 10.1016/j.jneuroim.2003.09.004.
37. Karni A, Abraham M, Monsonogo A, Cai G, Freeman GJ, Hafler D, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. *J Immunol*. (2006) **177**:4196–202. doi: 10.4049/jimmunol.177.6.4196.
38. Maghazachi AA. Role of Natural Killer Cells in Multiple Sclerosis. *ISRN Immunology*. (2012) **2012**:1–14. doi: 10.5402/2012/795075.
39. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. *Immunol Rev*. (2012) **248**:170–87. doi: 10.1111/j.1600-065X.2012.01135.x.
40. Compston A, Coles A. Multiple sclerosis. *Lancet*. (2002) **359**:1221–31. doi: 10.1016/S0140-6736(02)08220-X.
41. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. (2006) **354**:899–910. doi: 10.1056/NEJMoa044397.
42. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. *PLoS One*. (2013) **8**:e66308. doi: 10.1371/journal.pone.0066308.
43. Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. *Handb Clin Neurol*. (2014) **122**:173–89. doi: 10.1016/B978-0-444-52001-2.00008-X.
44. Setzu A, Lathia JD, Zhao C, Wells K, Rao MS, French-Constant C, et al. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. *Glia*. (2006) **54**:297–303. doi: 10.1002/glia.20371.
45. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. *J Exp Med*. (2000) **192**:899–905.

doi: 10.1084/jem.192.6.899.

46. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. *Nat Med.* (2005) **11**:146–52. doi: 10.1038/nm1177.
47. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. *Nat Neurosci.* (2011) **14**:1142–9. doi: 10.1038/nn.2887.
48. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. *J Leukoc Biol.* (2006) **80**:1298–307. doi: 10.1189/jlb.0406249.1.
49. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. *Immunity.* (2014) **41**:14–20. doi: 10.1016/j.immuni.2014.06.008.
50. Mikita J, Dubourdieu-Cassagno N, Deloie MS, Vekris A, Biran M, Raffard G, et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. *Mult Scler.* (2011) **17**:2–15. doi: 10.1177/1352458510379243.
51. Butovsky O, Landa G, Kunis G, Ziv Y, Avidan H, Greenberg N, et al. Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. *J Clin Invest.* (2006) **116**:905–15. doi: 10.1172/JCI26836.
52. Moliné-Velázquez V, Cuervo H, Vila-Del Sol V, Ortega MC, Clemente D, De Castro F. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. *Brain Pathol.* (2011) **21**:678–91. doi: 10.1111/j.1750-3639.2011.00495.x.
53. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. *Brain.* (2002) **125**:338–49. doi: 10.1093/brain/awf031.
54. Clemente D, Ortega MC, Melero-Jerez C, de Castro F. The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. *Front Cell Neurosci.* (2013) **7**:268. doi: 10.3389/fncel.2013.00268.
55. Deonaraine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, et al. Gene expression profiling of cutaneous wound healing. *J Transl Med.* (2007) **5**:11. doi: 10.1186/1479-5876-5-11.
56. Mirza R, DiPietro LA, Koh TJ. Selective and specific macrophage ablation is detrimental to wound healing in mice. *Am J Pathol.* (2009) **175**:2454–62. doi: 10.2353/ajpath.2009.090248
57. Godwin JW, Pinto AR, Rosenthal NA. Macrophages are required for adult salamander limb regeneration. *Proc Natl Acad Sci U S A.* (2013) **110**:9415–20. doi: 10.1073/pnas.1300290110.
58. Peiris TH, Hoyer KK, Oviedo NJ. Innate immune system and tissue regeneration in planarians: An area ripe for exploration. *Semin Immunol.* (2014) **26**:295–302. doi: 10.1016/j.smim.2014.06.005.
59. Robinson S, Miller RH. Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation. *Dev Biol.* (1999) **216**:359–68. doi: 10.1006/dbio.1999.9466.
60. Kotter MR, Li WW, Zhao C, Franklin RJM. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. *J Neurosci.* (2006) **26**:328–32. doi: 10.1523/JNEUROSCI.2615-05.2006.
61. McMorris FA, Dubois-Dalcq M. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. *J Neurosci Res.* (1988) **21**:199–209. doi: 10.1002/jnr.490210212.
62. McKinnon RD, Piras G, Ida JA Jr, Dubois-Dalcq M. A role for TGF-beta in oligodendrocyte differentiation. *J Cell Biol.* (1993) **121**:1397–407. doi: 10.1083/jcb.121.6.1397.

63. Yuen TJ, Johnson KR, Miron VE, Zhao C, Quandt J, Harrisingh MC, et al. Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination. *Brain*. (2013) **136**:1035–47. doi: 10.1093/brain/awt024.
64. Yu Z, Sun D, Feng J, Tan W, Fang X, Zhao M, et al. MSX3 Switches Microglia Polarization and Protects from Inflammation-Induced Demyelination. *J Neurosci*. (2015) **35**:6350–65. doi: 10.1523/JNEUROSCI.2468-14.2015.
65. Bodea LG, Wang Y, Linnartz-Gerlach B, Kopatz J, Sinkkonen L, Musgrove R, et al. Neurodegeneration by activation of the microglial complement-phagosome pathway. *J Neurosci*. (2014) **34**:8546–56. doi: 10.1523/JNEUROSCI.5002-13.2014.
66. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G et al. Identification of a Unique TGF- β Dependent Molecular and Functional Signature in Microglia. *Nat Neurosci*. (2014) **17**:131–43. doi: 10.1038/nn.3599.
67. Bennett ML, Bennett FC, Liddel SA, Ajami B, Zamanian JL, Fernhoff NB et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A*. (2016) **113**:E1738–46. doi:10.1073/pnas.
68. Kotter MR, Zhao C, van Rooijen N, Franklin RJM. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. *Neurobiol Dis*. (2005) **18**:166–75. doi: 10.1016/j.nbd.2004.09.019.
69. Bakker DA, Ludwin SK. Blood-brain barrier permeability during Cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. *J Neurol Sci*. (1987) **78**:125–37. doi: 10.1016/0022-510X(87)90055-4.
70. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. *J Exp Med*. (2014) **211**:1533–49. doi: 10.1084/jem.20132477.
71. Goldenberg MM. Multiple sclerosis review. *P T*. (2012) **37**:175–84.
72. Linehan E, Dombrowski Y, Snoddy R, Fallon PG, Kissenpfennig A, Fitzgerald DC. Aging impairs peritoneal but not bone marrow-derived macrophage phagocytosis. *Aging Cell*. (2014) **13**:699–708. doi: 10.1111/ace.12223.
73. Doring A, Sloka S, Lau L, Mishra M, van Minnen J, Zhang X et al. Stimulation of monocytes, macrophages, and microglia by amphotericin B and macrophage colony-stimulating factor promotes remyelination. *J Neurosci*. (2015) **35**:1136–48. doi: 10.1523/JNEUROSCI.1797-14.2015.
74. Franklin RJM, Gallo V. The translational biology of remyelination: Past, present, and future. *Glia*. (2014) **62**:1905–15. doi: 10.1002/glia.22622.

Figure legends

Figure 1: Innate immune cells in a demyelinated lesion can derive from activation of CX3CR1+ resident ramified microglia (green). Alternatively they may originate from blood monocytes (pink), which are recruited from the circulation in a CCR2-dependent manner and differentiate into macrophages. CX3CR1 and CCR2 have proved useful for genetically labeling or ablating the separate populations. Once activated, these cells become difficult to distinguish based on morphology and classical immunohistochemical techniques (striped), though some surface markers have recently been observed specifically in microglia, including Tmem119, P2ry12 and FCRL5. Innate immune cells can phagocytose inhibitory myelin debris and secrete an array of pro-regenerative factors, some of which are positively regulated by the transcription factor Msx3. The combination of these functions promotes the differentiation of OPCs (purple) and subsequent reinvestment of new myelin sheaths around denuded axons (blue).

Figure 01.JPEG

